UCB
Aesica aims to double capacity and turnover with UCB plants
December 20, 2010Manufacturing and Production Aesica, UCB, pharma manufacturing
UK contract manufacturer and ingredient supplier Aesica Pharmaceuticals is planning to double its production capacity with the acquisition of three …
UCB lupus candidate shows disease benefits
November 11, 2010Benlysta, Lupus, UCB, epratuzumab, monoclonal antibody, systemic lupus erythematosus
A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer …
‘Therapeutic clusters’ collaboration launched
November 2, 2010Research and Development ABPI, BIA, Immunology Initiative, Medical Research Council, Office for Strategic Co-ordination of Health and Research, Therapeutic Capability Clusters’, UCB, therapeutic clusters
Two initiatives linking the pharma industry and government-funded research and academia are to go ahead, with the aim of reviving …
UCB signs Parkinson’s research deal
October 12, 2010Research and Development Parkinson's, Synosia Therapeutics, UCB, neurology
UCB has partnered with Synosia Therapeutics to develop two of the Swiss firm’s compounds for Parkinson’s disease. Basel-based Synosia has …
Representing medium-sized pharma
September 16, 2010Sales and Marketing European Medicines Group, UCB
UCB’s Matthew Speers is the new chairman of the European Medicines Group, which represents European-owned pharma companies in the UK. …
New products help lift UCB
August 3, 2010Sales and Marketing 2010 financials, Q2, UCB
UCB’s newer products showed impressive growth in the first six months of this year, helping keep the Belgium-based biopharma firm’s …
UCB’s Speers to lead European Medicines Group
July 19, 2010Sales and Marketing European Medicines Group, UCB, appointment, sales and marketing
UCB Pharma’s managing director Matthew Speers has been elected chair of the European Medicines Group, taking over from Nigel Brooksby …
UCB’s new lupus treatment promising
June 17, 2010Research and Development Benlysta, Lupus, UCB, epratuzumab
A new monoclonal antibody treatment for lupus has shown promise in phase II trials, according to UCB. The biopharmaceutical company …
UCB’s Kola joins Astex board
June 5, 2010Research and Development Astex, UCB, appointment, research and development
Dr Ismail Kola has joined the board of directors at UK biotech company Astex Therapeutics. Astex’s non-executive chairman Peter Fellner …
Slow recovery expected for epilepsy market
May 27, 2010Sales and Marketing Datamonitor, Keppra, UCB, epilepsy
The global market for epilepsy treatments is expected to make a slow recovery after a wave of patent expiries from …
UCB’s Roch Doliveux joins Innovative Medicines Initiative board
May 19, 2010Research and Development UCB, appointment, research and development
UCB’s chief executive Roch Doliveux has joined the governing board of the Innovative Medicines Initiative. The IMI is a public-private …
Generic Keppra hits UCB sales
March 3, 2010Sales and Marketing 2009 financials, Keppra, UCB
UCB’s sales fell 13% in 2009 as the pharma company faced the first full year of generic competition in the …
Digital Pharma: UCB’s online epilepsy community
February 8, 2010Medical Communications, Research and Development PatientsLikeMe, UCB, community, digital pharma, digital pharma research, patient information
UCB has launched an online community for US epilepsy patients to record ‘real-world’ experiences of the condition. In addition to …
Patient access scheme secures NICE approval for Cimzia
January 22, 2010Sales and Marketing Cimzia, NICE, UCB, rheumatoid arthritis
UCB Pharma’s Cimzia has been recommended by NICE to treat rheumatoid arthritis – but only if a patient access scheme …
UCB and Novartis expand alliance in Germany
September 1, 2009Sales and Marketing Germany, Novartis, UCB
UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
